Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic trial demonstrates benefits of Resolute stent

Medtronic trial demonstrates benefits of Resolute stent

26th July 2011

Medtronic has published new data from a clinical study that supports the efficacy of its drug-eluting stent Resolute.

The medical device was evaluated in comparison to a leading alternative among 100 Japanese coronary artery disease patients, with in-stent late lumen loss being the primary measure of efficacy.

It was shown that Medtronic's stent was able to deliver superior performance to the control therapy according to criteria such as target lesion failure and stent thrombosis rates.

The Resolute stent was granted CE Mark approval in Europe in October 2007 and is currently available in more than 100 countries worldwide.

Medtronic intends to expand the availability of the device with the support of data from this study, as the stent is yet to be ratified for sale in the major markets of Japan and the US.

Earlier this month, Medtronic broadened the scope of its business with the acquisition of Salient Surgical Technologies, a developer of advanced energy systems for surgical applications.ADNFCR-8000103-ID-800634468-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.